Red Tree Venture Capital is an early stage-biased life science venture firm that leverages deep relationships with leading West Coast academic and research institutions to source innovation and build life science companies. The firm invests in therapeutics addressing unmet needs in oncology, neurology, and immunology.
40% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (47% of deals). Average disclosed round size is $91.7M (across 14 rounds with reported amounts).
Portfolio
12
Fund Size
$272M
Top Stage
Series A
Last 12 Mo
1
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
15 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Excellergy Inc. | Series A | $70M | Oct 2025 |
 KIVU BIOSCIENCE | Series A | $92M | Oct 2024 |
| EEngrail | Series B | $10M | Aug 2024 |
 Engrail Therapeutics | Series B | $157M | Mar 2024 |
| EEngrail | Series B | $157M | Mar 2024 |
 CARGO Therapeutics | Series A | $200M | Mar 2023 |
| CARGO Therapeutics | Series A | $200M | Jan 2023 |
 Rondo Therapeutics | Series A | $67M | Jan 2022 |
 Magnus Medical | Series A | $25M | Oct 2021 |
 Ceribell | Series C | $53M | Apr 2021 |
| Excellergy Inc. | Seed | — | Jan 2021 |
| TTachyon Therapeutics | Unknown | $11.6M | — |
 Bicara Therapeutics | Series B | $108M | — |
| BBicara | Series B | $108M | — |
| MMagnus | Series A | $25M | — |
Top Co-Investors
F-Prime Capital4 shared
Eight Roads4 shared
RA Capital Management3 shared
Samsara BioCapital3 shared
RTW Investments, LP2 shared
Wellington Management2 shared
Cormorant Asset Management2 shared
T. Rowe Price2 shared
Third Rock Ventures2 shared
Ally Bridge Group2 shared
Emerson Collective2 shared
Ysios Capital2 shared
Longwood Fund2 shared
RiverVest Venture Partners2 shared
Forbion2 shared
Pivotal Life Sciences2 shared
Norwest Venture Partners2 shared
Novo Holdings A/S2 shared
JAZZ Venture Partners2 shared
Last updated: 27 September 2026